Press Releases

NORTH CHICAGO, Ill., June 25, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review a supplemental New Drug Application (sNDA) for IMBRUVICA^® (ibrutinib) in combination with rituximab (RITUXAN^®) as a new treatment option for Waldenström's macroglobulinemia (WM), a rare and incurable form of blood cancer.¹ If approved, the sNDA would expand the prescribing information of IMBRUVICA in WM beyond its current approved use as a single agent for all lines of therapy to include combination use with rituximab. As a single-agent therapy, IMBRUVICA is the first and only FDA-approved treatment available for patients with WM. IMBRUVICA is a first-in-class Bruton's tyrosine kinase (BTK) inhibitor jointly developed and commercialized by Pharmacyclics LLC, an AbbVie company, and Janssen Biotech, Inc.

NORTH CHICAGO, Ill. and LA JOLLA, Calif., June 25, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Calibr, a nonprofit drug discovery division of Scripps Research, today announced a collaboration to develop T-cell therapies aimed primarily at cancer, including solid tumors.

NORTH CHICAGO, Ill., June 19, 2018 /PRNewswire/ -- AbbVie, a global biopharmaceutical company, has teamed up with leading nonprofits to launch its fifth annual "Week of Possibilities" global volunteering program. In more than 50 countries, approximately 8,000 AbbVie employees will give 36,000 service hours in communities where they live and work, completing hands-on volunteer projects that enhance education and opportunities for the underserved.

NORTH CHICAGO, Ill., June 15, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the presentation of investigational data from a new analysis of undetectable minimal residual disease (uMRD) rates from the pivotal Phase 3 MURANO trial of venetoclax, a first-in-class oral B-cell lymphoma-2 (BCL-2) inhibitor, in combination with rituximab (VenR) in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL). Of the 121 patients who achieved uMRD (meaning less than one CLL cell in 10,000 white blood cells were detectable using a standardized test²) at the end of combination therapy (EOCT), 83 percent (n=100) maintained uMRD and were progression-free for a median of 13.8 months (range, 5.6-23.0 months) thereafter. These results will be presented in an oral session on Saturday, June 16, at 11:45 a.m. CEST during the 23^rd European Hematology Association (EHA) Annual Congress in Stockholm.¹  Venetoclax is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S.

NORTH CHICAGO, Ill., June 14, 2018 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $0.96 per share. 

NORTH CHICAGO, Ill., June 12, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today presented new patient-reported outcome data during the Annual European Congress of Rheumatology (EULAR 2018) in Amsterdam from three Phase 3 trials evaluating upadacitinib, an investigational, once-daily oral JAK1-selective inhibitor, in adult patients with moderate to severe rheumatoid arthritis.^1,2,3 Improvements in pain, physical function and morning joint stiffness were reported after 12 weeks of treatment with upadacitinib (15 mg and 30 mg, once-daily) in SELECT-NEXT and SELECT-BEYOND and after 14 weeks of treatment in SELECT-MONOTHERAPY.^1,2,3 Additionally, improvements were reported in fatigue and work instability in SELECT-NEXT and patients' physical component of health-related quality of life in SELECT-NEXT and SELECT-BEYOND at 12 weeks.^1,2 Upadacitinib is not approved by regulatory authorities and its safety and efficacy have not been established.

NORTH CHICAGO, Ill., June 8, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has approved, under priority review, VENCLEXTA® (venetoclax tablets) in combination with rituximab for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy.¹

NORTH CHICAGO, Ill., June 5, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive top-line results from SELECT-EARLY showing that both doses of upadacitinib monotherapy (15 mg and 30 mg) met the primary endpoints of ACR50^a at week 12 and clinical remission^b at week 24 versus methotrexate (MTX).¹ Additionally, all ranked secondary endpoints were met.¹ The ongoing study evaluates upadacitinib, an investigational oral JAK1-selective inhibitor, as a monotherapy treatment compared to methotrexate monotherapy in adult patients with moderate to severe rheumatoid arthritis who were methotrexate-naïve.¹ Upadacitinib is not approved by regulatory authorities and its safety and efficacy have not been established.

NORTH CHICAGO, Ill., June 4, 2018 /PRNewswire/ -- AbbVie, a research-based global biopharmaceutical company, today announced the launch of Voices of HS Unite, a global social media effort to connect and inspire those impacted by hidradenitis suppurativa (HS), a painful, chronic, inflammatory skin disease. The program, which is launching during HS Awareness Week (4 – 10 June), encourages people affected by the disease to share their stories on social media using #HSHope in their native language. Through connecting and empowering HS patients around the world, AbbVie aims to help strengthen the global HS community and to encourage patients to discuss their condition with a dermatologist.

NORTH CHICAGO, Ill., June 4, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the final results of its modified Dutch auction tender offer, which expired at 12:00 midnight, New York City time, at the end of May 29, 2018.